discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

offering a new therapeutic target for Parkinson's and other movement ... Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder ...